NCT00640588View on ClinicalTrials.gov

Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Hepatitis B, Chronic
Interventions
DRUG

Telbivudine

Arm 1: 600 mg/day, oral telbivudina for 24 weeks

DRUG

oral adefovir

Arm 2: 600 mg/day, oral telbivudina plus 10 mg/day oral adefovir for 24 weeks

Trial Locations (1)

Unknown

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY